4',5'-Didehydro-5'-deoxyadenosine manufacturers
|
| | 4',5'-Didehydro-5'-deoxyadenosine Basic information |
| Product Name: | 4',5'-Didehydro-5'-deoxyadenosine | | Synonyms: | 4',5'-Didehydro-5'-deoxyadenosine;CALCIUM BIS(CYCLOHEXYLSULFAMATE);Adenosine, 4',5'-didehydro-5'-deoxy-;4’,5’-Didehydro-5’-deoxyadenosine, 1-(5-Deoxy-beta-D-erythro-pent-4-enofuranosyl)adenine;1-(5-Deoxy-beta-D-erythro-pent-4-enofuranosyl)adenine | | CAS: | 20535-04-0 | | MF: | C10H11N5O3 | | MW: | 249.23 | | EINECS: | | | Product Categories: | | | Mol File: | 20535-04-0.mol |  |
| | 4',5'-Didehydro-5'-deoxyadenosine Chemical Properties |
| Melting point | 195-196 °C (decomp)(Solv: methanol (67-56-1); acetone (67-64-1)) | | Boiling point | 591.1±60.0 °C(Predicted) | | density | 1.91±0.1 g/cm3(Predicted) | | pka | 13.15±0.60(Predicted) |
| | 4',5'-Didehydro-5'-deoxyadenosine Usage And Synthesis |
| Uses | 4′,5′-Didehydro-5′-deoxyadenosine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc[1]. | | References | [1] Robak T, Robak P. Purine nucleoside analogs in the treatment of rarer chronic lymphoid leukemias. Curr Pharm Des. 2012;18(23):3373-88. DOI:10.2174/138161212801227005 |
| | 4',5'-Didehydro-5'-deoxyadenosine Preparation Products And Raw materials |
|